(WSJ) – A well-designed system could help us understand better what we don’t know as well as what we do.

Stung by disappointment, seasoned drug developers approach AI with only cautious enthusiasm. But the aspiration to deliver tailored health advice to consumers is back with a vengeance, now equipped with a richer instrument panel and AI to connect the dots.

Sometimes this can be useful. But richer data, combined with AI’s ability to integrate and interpret them, also create a risk of false precision—recommendations that feel more individualized, and more certain, than the evidence warrants. (Read More)